

Market Announcement

4 December 2024

Cynata Therapeutics Limited (ASX: CYP) – Trading Halt

Description

The securities of Cynata Therapeutics Limited ('CYP') will be placed in trading halt at the request of CYP, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 6 December 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

ASX Compliance
Level 50, South Tower
Rialto, 525 Collins Street
Melbourne VIC 3000

By email: tradinghaltsmelbourne@asx.com.au

Request for Trading Halt

Cynata Therapeutics Limited (“**Cynata**” or “the **Company**”) (ASX:CYP) requests that its securities be placed into an immediate trading halt.

In accordance with Listing Rule 17.1, the Company advises:

- (a) the trading halt is requested by the Company in relation to a pending announcement of the results of the phase 1 clinical trial in diabetic foot ulcers;
- (b) the Company requests that the trading halt remain in place until the earlier of the Company releasing the announcement and the opening of trading on Friday, 6 December 2024;
- (c) the Company is not aware of any reason why the trading halt should not be granted; and
- (d) the Company is not aware of any other information necessary to inform the market about the trading halt.

-ENDS-

Authorised for release by the Board of Directors

CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, lauren@littlebigdeal.au

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. A Phase 2 clinical trial in GvHD under a cleared US FDA IND, as well as trials of Cymerus products in osteoarthritis (Phase 3 – patient enrolment completed) and diabetic foot ulcers (DFU – patient enrolment completed) are currently ongoing, while a trial in renal transplant is expected to commence in the near future. In addition, Cynata has also demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.